Hypothesis

The age‑related rise in mismatch‑repair deficiency and field carcinogenesis in the colon is not merely accumulated damage but the output of a conserved inflammatory program that was selected to limit stem‑cell clonal expansion early in life. This program, now active post‑reproductively, enforces a homeostatic ceiling on mutant clone size; interfering with it should reduce late‑life cancer risk without compromising early‑life tissue renewal.

Background

Epidemiological data show colorectal cancer incidence doubling each decade after 40 and a sharp increase in dMMR tumors in individuals over 80, especially women [1, 2]. Experimental work demonstrates that inflammatory cytokines are required for the expansion of mutated clones in field carcinogenesis [3] and that DNMT3A/TET2‑mutant clonal hematopoiesis expands via similar pro‑inflammatory signaling [4]. These observations fit antagonistic pleiotropy: pathways that boost early‑life fitness (e.g., rapid epithelial repair) become deleterious later.

Mechanistic Insight

We propose that a specific cytokine axis—IL‑6 trans‑signaling via soluble IL‑6R—acts as an evolutionary “brake” on stem‑cell progeny. In youth, transient IL‑6 bursts promote barrier regeneration after injury while simultaneously activating STAT3‑dependent expression of differentiation inducers that keep stem‑cell numbers in check. With age, cumulative mitochondrial dysfunction and low‑grade NF‑κB activation cause chronic IL‑6 trans‑signaling, converting a pulse‑like brake into a sustained signal that paradoxically fuels mutant clone expansion by sustaining a proliferative niche while suppressing immune surveillance.

Experimental Plan

1. Model – Use aged (20‑month) Apc^min/+ mice that develop intestinal tumors; include sex‑matched cohorts to capture the female‑biased dMMR pattern.
2. Intervention – Treat mice with sgp130Fc, a selective inhibitor of IL‑6 trans‑signaling, or with control IgG, beginning at 18 months and continuing for 6 months.
3. Readouts –
   • Quantify dMMR frequency (MLH1/PMS2 IHC) and tumor burden.
   • Measure clonal expansion of Lgr5^+ stem cells via lineage tracing.
   • Assess inflammatory cytokines (IL‑6, sIL‑6R) and STAT3 phosphorylation in crypts.
   • Monitor early‑life fitness proxies (wound healing rate, crypt regeneration after DSS injury) in a parallel young cohort treated identically.
4. Falsifiable Prediction – If IL‑6 trans‑signaling constitutes an evolved brake, its inhibition will (a) reduce dMMR‑positive tumor incidence and clonal expansion in aged mice (b) without impairing acute injury repair or stem‑cell renewal in young mice.

Expected Outcomes

• A significant decrease (>30%) in dMMR tumors and overall neoplasia in treated aged mice versus controls.
• Lineage‑tracing shows smaller mutant clone sizes, indicating restrained expansion.
• No statistically significant delay in epithelial restitution after DSS colitis in young treated mice, confirming that early‑life regenerative capacity remains intact.

Implications

Confirming this hypothesis would reframe aging‑associated cancer risk as the dysregulation of an adaptive, population‑level mechanism rather than passive wear‑and‑tear. Therapeutic strategies would then aim to modulate, not abolish, the inflammatory brake—potentially preserving its beneficial early‑life functions while mitigating its maladaptive late‑life consequences.